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ABSTRACT  
Incidence of and risk factors for infectious complications in patients with cardiac device implantation 
patients with cardiac device implantation 
 
Hea Won Ann 
 
Department of Medicine  
The Graduate School, Yonsei University  
 
(Directed by Professor Jun Yong Choi) 
 
Objectives: The use of cardiac implantable electronic device (CIED; pacemakers, implantable 
cardioverter-defibrillators [ICD], cardiac re-synchronized therapy [CRT]) implantation, one essential 
treatment for cardiac arrhythmias, is increasing. Infectious complications related to implants are the 
main reason for device removal and patient morbidity. We sought to identify the incidence of 
infectious complications among patients with cardiac device implantation and analyze the risk factors 
for infectious complications.  
   
Methods: A retrospective analysis was conducted of 1307 patients (61.5±14.2 years-old, 49.6% male) 
with cardiac device implantation from January 1990 to April 2013. We analyzed the incidence of 
infectious complications during the follow-up period. To investigate risk factors associated with 
infectious complications, we conducted a 1:2 matched case-control study of patients with infectious 
complications and controls without infectious complications who had the same implantation period 
and physician.   
   
Results: Among 1307 patients, 12 had a confirmed device-related infection: 7 with a pocket infection 
and 5 with infective endocarditis. Over a total of 9091.9 device-years, the incidence of infectious 
complications was 1.3/1000 device-years, based on the 12 patients with an infection. ICD (5.1/1000 
device-year) had a higher incidence of infectious complications than other cardiac devices, and no 
infectious complications were observed among patients with CRT implantation. Mean duration from 
the time of implantation to infection was 2.02±1.65 years. In a multivariate analysis, the number of 
prior procedures including wound revision or scar revision was an independent risk factor for 
infectious complications (OR=10.88, 95% CI 1.11->999, p=0.040).   
  
Conclusions: Infection was a rare complication of cardiac device implantation, but repeated 
procedures were associated with infectious complications. 
 
------------------------------------------------------------------------------------------------------------- 
Key words: cardiac pacemaker, artificial, defibrillators, implantable, cardiac resynchronization 
therapy, infection  
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I. INTRODUCTION 
The use of cardiac implantable electronic device (CIED; pacemakers, implantable cardioverter-
defibrillators [ICD], cardiac re-synchronized therapy [CRT]) implantation, an essential procedure to 
treat cardiac arrhythmias, is growing. Pacemaker and ICD implantation has increased by 19% and 
60%, respectively, from 1997 to 2004 in the United States.1 A rising trend has been observed globally, 
including in Korea.2,3 The reported incidence of cardiac device-related infections ranges from 0.5%-
4.8%.4-7 Although infrequent, infectious complications can cause device removal and even mortality.8-
13 Recent research shows that diabetes mellitus, underlying heart disease, CRT/dual chamber devices 
and use of >1 lead are risk factors for cardiac device-related infection.11,14,15 Most research on cardiac 
device-related infections has been conducted in Western countries, and studies in Asian countries are 
limited. The current incidence of cardiac device-related infections in South Korea is unknown, 
although implantation of cardiac devices has been performed there since 1969.16 There were 5,815 
cases of cardiac device implantation in 2006 and 9,208 cases in 2013 in South Korea.17,18 A better 
understanding of the incidence and risk factors of infectious complications in the region would help 
physicians develop appropriate measures to prevent and treat cardiac device-related infections. 
We conducted this study to investigate the incidence and risk factors of cardiac device-related 
infections in South Korea.  
 
II. MATERIALS AND METHODS 
1. Study population  
The study population was composed of patients who underwent cardiac device (including permanent 
pacemakers, ICD, CRT) implantation de novo in a 2,000-bed, tertiary teaching hospital from January 
1990 to April 2013 in South Korea. A retrospective analysis was conducted using the medical records 
of 1,306 patients, aged 18 years or older, for whom clinical observations and laboratory findings were 
3 
 
available. We excluded patients who did not receive regular follow-up or who received an implant in 
another hospital but came to our center with an infection. 
 
2. Study design and variables 
We analyzed the incidence of cardiac device infections among 1,307 patients during the follow-up 
period. Person-years of follow-up were calculated from the date of cardiac device implantation until 
the date of cardiac device infection or the date of last follow-up visit at the hospital.  
Diagnosis of cardiac device infection was made clinically or microbiologically. We defined clinical 
evidence of cardiac device infection as one of the following signs: erythema, tenderness, fluctuance, 
warmth, wound dehiscence, skin erosion or discharge over the generator site.19 Microbiological 
diagnosis was made based on positive culture of typical causative agents from the pocket of the 
device or its leads.19 We applied modified Duke Criteria for the diagnosis of infective endocarditis for 
the detection of device-related endocarditis.20 
 
In addition, to identify risk factors for cardiac device infection, we performed a matched case-control 
study. Cases included 12 patients with device-related infections during the study period. The control 
group consisted of 24 patients who underwent cardiac device implantation during the same period 
without infections during follow-up. Two controls were matched to each case according to 
implantation period within a month and the physician who did the procedure.  
 
The following variables were assessed: (1) demographic and clinical characteristics (age at cardiac 
device implantation, gender, body mass index and Charlson comorbidity index.21 Presence of arterial 
hypertension, diabetes, myocardial infarction, heart failure (ejection fraction < 50%), valve disease 
(significant regurgitation or stenosis in transthoracic echocardiography), chronic obstructive 
pulmonary disease (FEV1/FVC <70%), renal insufficiency (estimated glomerular filtration rate 
<60mL/min/1.73㎡), malignant neoplasm and smoking were assessed.; (2) perioperative 
circumstances (use of prophylactic antibiotics, presence of signs of infection, anticoagulants use); (3) 
device characteristics (type of device - pacemaker, implantable cardioverter-defibrillator, cardiac 
resynchronized therapy,  number of intracardiac leads); (4) number of procedures before the 
infection occurred (generator change, wound revision, lead repositioning and temporary pacemaker 
use). 
 
3. Data analysis 
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Normally distributed continuous variables were expressed as mean ± standard deviation (SD).  
Statistical significance of the comparisons was assessed using the paired t-test and χ2 test. Uni- and 
multi-variate logistic regression analyses were used to analyze the cause of device-related infection 
between cases and controls. Variance inflation factors (VIF) were used to measure co-linearity in the 
multivariate logistic analysis; parameters with VIF≥10 were considered to be co-linear. Parameters 
with co-linearity were excluded from the multivariate logistic regression analysis. A p-value <0.05 
was considered statistically significant. Analyses were performed using SPSS v19 (SPSS Inc., 
Chicago, IL, USA) and SAS version 9.2 (SAS Institute Inc., Cary, NC, USA.) 
 
III. RESULTS 
A total of 1307 patients underwent cardiac device implantation during the study period. Of these, 
49.6% were male, and the mean age was 61.5±14.2 years. There were 1,130 patients (86.5%) who 
received pacemaker implantation, 147 (11.2%) who received an ICD and only 30 patients (2.3%) who 
received CRT. Over a total of 9,091.9 device-years, the incidence of infectious complications was 
1.3/1000 device-years (Table 1), based on the 12 patients with an infection. There was a higher 
incidence of infectious complications with ICD (5.1/1000 device-year) than other cardiac devices, and 
no infectious complications were observed among the patients with CRT implantation. Of the 12 
patients with infection, 7 patients (0.5%) had a pocket infection only and 5 patients (0.4%) had 
infective endocarditis. The mean duration from the time of implantation to infection (range) was 
2.02±1.65 years (6 days to 2481 days) (Table 1).  
 
Table 1. Incidence of infectious complications of cardiac implantable electronic devices 
    Device type   
  Total PM ICD CRT p-value 
Number (n,%) 1,307 1,130 (86.5) 147 (11.2) 30 (2.3)  
Age (Years) 61.5±14.2 62.5±13.7 53.6±14.7 64.1±13.6 <0.001 
Gender (male; n,%) 634 (49.6) 496 (44.0) 123 (83.7) 15 (50.0) <0.001 
Total FU duration (Device-yr) 9,091.95 8,442.27 579.99 69.68  
No. of infection complications (n,%) 12 (0.9) 9 (0.8) 3 (2.0)   
Incidence (/1,000Device-yr) 1.3 1.0 5.1   
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    Device type   
  Total PM ICD CRT p-value 
Type of infection      
  Pocket infection (n,%) 7 (0.5) 5 (0.4) 2 (1.4)   
  Endocarditis (n,%) 5 (0.4) 4 (0.4) 1 (0.7)     
PM: Pacemaker, ICD: implantable cardioverter defibrillator, CRT: cardiac resynchronized therapy, FU: follow-
up 
 
Table 2 compares demographic and clinical characteristics between patients with and without 
infections complications. There were no significant differences in gender, echocardiographic findings 
or lab findings between the two groups. The proportion of patients with renal insufficiency and 
valvular heart disease was higher in the control group than the case group, and there was no 
significant difference in the prevalence of diabetes mellitus. The Charlson comorbidity index was 
higher in the control group, but was an insignificant variable in the multivariate analysis (p=0.0936) 
(Table 3). The multivariate analysis indicated that patients with infection had a greater number of 
prior procedures including wound revision, generator exchange or scar revision (OR=10.87, 95% CI 
1.108->999, p=0.0402) (Table 3).  
 
Table 2. Comparison of demographic and clinical characteristics in patients with and without 
infectious complications: Case control study (1:2 matched) 
  Control (n=24) Case (n=12) p-value 
Age 68.5±12.3 56.7±18.0 0.056 
Gender (male ; n,%) 13 (45.80) 7 (41.07) 0.819 
Device and procedure related factors  
     No. of leads 1.5±0.5 1.8±0.5 0.224 
     No. of prior procedures 0.04±0.21 0.75±1.1 0.056 
     Hematoma 4.20% 8.30% 0.619 
     Antiplatelet agent 41.70% 25.00% 0.393 
     Hospital duration 5.3±1 2.9±1.9 0.078 
Underlying disease  
     Hypertension (n,%) 16 (66.70) 5 (41.7) 0.16 
     Diabetes mellitus (n,%) 7 (29.20) 1 (8.3) 0.109 
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  Control (n=24) Case (n=12) p-value 
     Myocardial infarction (n,%) 1 (4.2) 2 (16.7) 0.314 
     Heart failure (n,%) 3 (12.5) 1 (8.3) 0.717 
     Valve disease (n,%) 13 (54.20) 2 (16.7) 0.032 
COPD (n,%) 0 (0) 0 (0) - 
     Renal disease (n,%) 4 (16.60) 0 (0) 0.043 
     Cancer (n,%) 0 (0) 0 (0) - 
     Charlson comorbidity index 2.1±2.8 0.5±0.80 0.014 
     Smoking (n,%) 7 (29.20) 4 (33.3) 0.805 
Echocardiographic findings  
     Ejection fraction 62.9±6.2 64.8±10.3 0.718 
     E/E' 14.0±5.8 11.0±4.0 0.176 
Laboratory findings  
     WBC (10^3/uL) 7488.8±3017.8 6876.7±1568.2 0.516 
     Neutrophil (%) 59.3±14.3 56.9±14.5 0.634 
     Hemoglobin (g/dL) 13.2±1.6 13.9±1.9 0.262 
     Platelet (10^3/uL) 234.6±92.5 233.1±46.7 0.958 
     Hemoglobin A1c (%) 6.7±0.9 6.5±0.6 0.69 
     Creatinine (mg/dL) 1.1±0.4 0.9±0.2 0.122 
     eGFR (ml/min/1.73m²) 72.0±25.5 93.7±28.6 0.031 
     CRP (mg/L) 24.8 30.7±42.1 0.929 
     NTproBNP (pg/mL) 1033.9±1546.8 216.4±127.6 0.182 
     CK (IU/L) 137.4±124.2 78 0.368 
     CK-MB (ng/mL) 3.7±4.1 1.8±0.3 0.441 
     TnT (ng/mL) 0.03±0.077 0.01±0.01 0.536 
     AST (IU/L) 32.4±19.6 21.3±6.2 0.065 
     ALT (IU/L) 41.1±47.2 20.9±11.7 0.058 
COPD: chronic obstructive pulmonary disease, WBC: white blood cell, eGFR: estimated glomerular filtration 
rate, CRP: C - reactive protein, NTproBNP: N-terminal prohormone of brain natriuretic peptide, CK: creatine 
kinase, TnT: troponin T, AST: aspartate aminotransferase, ALT: alanine aminotransferase 
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Table 3. Risk factors for device-related infections by univariate and multivariate conditional logistic 
regression analysis 
  Univariate analysis   Multivariate analysis 
  OR 95% CI p-value   OR 95% CI p-value 
Age 0.948 0.899 0.995 0.0304 
 
1.02 0.932 1.13 0.72 
Gender 0.848 0.162 4.195 1 
     
Hospital duration 0.73 0.443 1.01 0.0619 
     
Charlson score 0.6 0.265 1.002 0.0517 
 
0.523 0.103 1.067 0.0936 
No. of leads 2.475 0.458 17.784 0.4001 
     
No. of prior procedures 19.334 1.682 >999 0.011 
 
10.872 1.108 >999 0.0402 
Ejection fraction 1.01 0.961 1.068 0.7504 
     
OR: odds ratio, CI: confidence interval 
 
Table 4 lists the clinical characteristics of each patient with cardiac device infection. The 
pathogens thereof were identified in six patients, and included Staphylococcus aureus (S. aureus), two 
cases of coagulase-negative staphylococcus, Enterococcus faecium, and two cases of gram negative 
bacilli (Enterobacter cloacae, Escherichia coli). The device was removed in all patients: four through 
open heart surgery and eight through percutaneous extraction.  
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Table 4. Clinical characteristics of each patient with a cardiac device infection 
  Age Gender Local manifestation Fever TTE Device 
type 
Prior 
procedure 
Time 
interval 
Local culture Lead culture Blood 
culture 
Outcome  
1 80 F Inflammation (redness, 
discharge) 
+ - PM 0 6 Negative  Negative  Negative  Percutaneous 
extraction 
Recurrent 
skin eruption 
over the 
implantation 
site 
2 73 F Inflammation (hematoma, 
serosanguineous 
discharge) 
- - PM 0 10 Negative  Negative  Negative  Percutaneous 
extraction 
 
3 60 M Inflammation (skin 
discoloration, tenderness) 
- - PM 1 (wound 
revision) 
34 Enterobacter 
cloacae  
Enterobacter 
cloacae  
Negative  Percutaneous 
extraction 
Overlying 
skin thinning 
and necrosis 
4 38 F Inflammation (redness, 
local heating, tenderness) 
+ Negative ICD 2 (pacemaker 
revision, scar 
revision) 
65 MRSA  MRSA  MRSA  Surgical  
removal 
Pacemaker 
insertion under 
the left 
pectoralis 
major muscle 
via the axillary 
incision 
(cosmetic 
cause) 
5 34 M Inflammation (yellowish 
pus) 
- - PM 1 (generator 
repositioning) 
191 Negative  Negative  Negative  Percutaneous 
extraction 
 
6 73 F Inflammation (yellowish 
discharge, skin defect) 
- - ICD 0 468 Negative  -  Negative  Surgical  
removal 
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  Age Gender Local manifestation Fever TTE Device 
type 
Prior 
procedure 
Time 
interval 
Local culture Lead culture Blood 
culture 
Outcome  
7 43 M Erosion, tenderness - - PM 0 566 Negative  Negative  Negative  Percutaneous 
extraction 
 
8 57 M Inflammation (swelling, 
tenderness) 
- - PM 1 (re-
implantation 
with device 
protrusion) 
611 MRCNS  MRCNS  Negative  Percutaneous 
extraction 
 
9 39 F Inflammation (pus 
discharge) 
- - PM 1 (generator 
repositioning) 
876 E.faecium  Negative  Negative  Percutaneous 
extraction 
 
1 0 69 M Inflammation (skin 
erosion, discharge) 
- - PM 2 (wound 
debriment and 
revision) 
938 MSCNS  MSCNS  Negative Surgical  
removal 
 
1 1 79 F Inflammation (skin 
erosion, wire exposure) 
+ Vegetation PM 0 1013 Negative  Negative  Negative  Surgical  
removal 
Skin erosion 
by nail 
scratch, 
secondary 
septic 
pneumonia  
1 2 35 M Inflammation (wound 
dehiscence, pus-like 
discharge) 
-  Negative  ICD 1 (lead 
exchange) 
2481 ESBL (-) 
E.coli  
-  Negative Percutaneous 
extraction 
 
TTE: Transthoracic echocardiography, MRSA: Methicillin–-resistant staphylococcus aureus, MRCNS: Methicillin-resistant coagulase negative staphylococci, MSCNS: Methicillin-sensitive 
coagulase negative staphylococci, ESBL: Extended spectrum beta-lactamase
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IV. DISCUSSION 
To our knowledge, this is the first report of infections associated with cardiac devices in Korea. The 
long period of observation allowed us to review long term prognosis of Asian patients with cardiac 
devices. Device-related infection was a rare complication, and repeated procedures were associated 
with infectious complications. 
 
According to prior studies, cardiac device-related infection occurs in about 0.5-3.5% of cases, with 
an incidence that varies from 0.55 to 4.82 per 1000 device-years.5,8-12 CIED-related infection 
increased 5.8% from 1996 to 2006 even though CIED implantation only increased 2.6% during the 
same time period.15,22 In our study, 0.9% of patients with cardiac devices had infectious complications, 
and the overall incidence was 1.3/1000 device-years. This low incidence matches those reported in 
previous studies. Nevertheless, the indications for CIED implantation are widening23,24,25 and the 
number of patients susceptible to infection (due to old age and various underlying diseases) is 
increasing. Thus, the actual number of cases of CIED infection may greatly expand in the near future. 
Despite its low incidence, CIED infection is an important complication, the consequences of which 
are quite serious: endocarditis related with device infection increases mortality26,27, and most cases 
require device removal28,29, which involves risks of cardiac perforation or open thoracotomy.30  
 
Several earlier studies showed that factors associated with procedures included early intervention, 
more than two leads, device replacement or revision and placement of temporary pacing wire.1,8,12,14 
Patient-related factors included diabetes, renal failure, heart failure and male sex.1,12,31. Some 
researchers have pointed out that corticosteroids or anticoagulation are related to CIED 
infection.8,12,28,31,32 There have also been some reports that the number of cardiac device operations is 
independently related to a higher risk of infection.12,33  
In our case-control study, repeated procedures were a significant risk factor for infectious 
complications. This finding is consistent with previous studies. We were unable to analyze the 
influence of renal dysfunction or heart failure because of the low incidence of these diseases in our 
study population. Herce et al. evaluated risk factors for infection of implantable cardiac devices with 
data from a registry of 2469 patients in a French hospital between 1996 and 2007.1 Their study 
showed the presence of diabetes and underlying heart disease to be risk factors for infection after 
cardiac device implantation. Meanwhile, others have reported contrasting results. In a report by 
Greenspon et al., CIED infection was lower in patients with diabetes (Odds ratio: 0.91; 95% CI: 0.86 
to 0.96; p <0.001)34, and others described diabetes as an insignificant risk factor.8,32 In our study group, 
the prevalence of diabetes in the case group (29.2%) was insignificantly higher than that in the control 
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group (8.3%); moreover, the presence of diabetes was not shown to be an independent risk factor for 
infectious complications in our case control study, even after including diabetes in the multivariate 
model. Diabetes mellitus is usually related with wound infection, but has no negative influences under 
tight glycemic control.35,36 In the present study, diabetes in all enrolled patients was controlled well, 
with a mean HbA1c of 6.55±0.52%. Thus, we suggest that the burden of repeatedly undergoing 
medical procedures influences the occurrence of CIED infection much more than patient 
characteristics, including underlying disease. 
 
In our study, the pathogens of infectious complications were identified in only 6 patients. Previous 
studies showed that bacterial infection is the leading cause of CIED complication, mostly from skin 
normal flora37, among which S. aureus and coagulase negative staphylococcus comprise the majority 
of infections38,39. In our study participants, one case of S. aureus and two cases of coagulase negative 
staphylococcus were observed. The S. aureus and one of the coagulase negative staphylococcus 
cultures were methicillin resistance. Reportedly, the risk of methicillin-resistance is higher within a 
year of implantation40; however, in our study, we could not find a distinct relationship in patients with 
methicillin-resistant bacteria, due to the small sample size.  
 
We also observed a relatively higher infection rate in patients with ICD implantation (statistically 
insignificant). The ICD generator is bigger and heavier than pacemakers, and thus requires a longer 
incision and bigger pocket. Patients with ICD exhibit more tension on covering skin and a chance of 
bigger dead space. As well, most patients that require ICD are survivors of cardiac arrest. Cardiac 
arrest and resuscitation cause cardiac stunning and transient multiple organ injury. Although their 
cardiac dysfunction reversed fully from stress, these systemic effects could have had a negative 
influence on their general condition and a chance of infection. 
 
All of the patients with device infection had their devices removed. Eight patients underwent 
percutaneous removal, and the other 4 patients underwent open thoracotomy. There was no CIED 
infection-related death in our study participants. The reported inpatient mortality related with CIED 
infection ranges from 4.69% to 17% in cases of endocarditis.34,41,42 
 
Limitations 
This study has several limitations. First, this is a retrospective study. We could not analyze the 
effect of renal insufficiency or heart failure because there were only few patients with comorbidities. 
We only included patients from a single referral center, and so our findings may not be broadly 
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applicable. Despite these limitations, this is the first report about the incidence and risk factors of 
CIED infection in South Korea. And it is meaningful that we saw long term after-effects associated 
with cardiac device implantation over 23 years of observation (1990-2013).  
Our findings could be helpful in the both clinical setting and further research on CIED infections. 
 
V. CONCLUSION 
Even though the incidence of CIED-related infections was low in South Korea, physicians should 
closely monitor for complications in patients who receive repeated procedures. 
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ABSTRACT(IN KOREAN) 
 
삽입형 심장 전자장치 감염 환자의 발생 빈도 및 위험인자 
 
<지도교수  최준용> 
 
연세대학교 대학원 의학과 
 
안 혜 원 
 
 
목적: 삽입형 심장 전자장치(영구 심박동기, 삽입형 심실제세동기, 심장 재동기화 치료)  
는 심장 부정맥을 치료하는 데 중요한 방법이며 시술 건수가 급격히 증가하고 있다. 삽
입형 심장 전자장치와 관련한 감염증은 주요한 부작용으로, 발생 시에 장치를 제거해야
하며 사망률과도 관련이 높다. 본 연구에서는 삽입형 심장전자장치 관련 감염증의 발생 
빈도와 위험인자를 분석하였다. 
방법 : 1990년 1월부터 2013년 4월까지 세브란스병원에서 처음으로 삽입형 심장 전자장
치를 시술 받은 성인환자를 대상으로 하였다. 모든 환자를 대상으로 관찰기간을 조사하
여 발생빈도를 산출하였다. 위험인자 분석을 위해 감염증이 발생한 환자군과, 시술자, 
시술 시기가 일치하는 비교군을 1:2 로 선정하였다. 
결과: 총 1307명의 환자(61.5±14.2 세, 남자 49.6%) 중 12명의 감염증 환자가 발생하였
다. 7명은 박동기 주머니 감염이, 5명에서는 심내막염이 발생하였다. 총 관찰기간은 
9091.9 장치-년이었으며 발생빈도는 1,000 장치-년 당 1.3건이었다. 삽입형 심실제세동
기를 시술받은 환자에서는 발생빈도가 1,000 장치-년 당 5.1건으로 영구심박동기의 
1,000 장치-년 당 1.0건보다 높았다. 심장 재동기화 치료에서는 감염증이 발생하지 않았
다. 감염증은 시술 후 평균 2.02±1.65 년 후에 발생하였다. 다변량 회귀분석에서 반복
되는 재시술 (발생기 교체, 흉터 재수술)이 유의한 위험인자로 분석되었다. (위험도 
10.88, 95% 신뢰구간 1.11->999, p-value 0.04) 
결론: 삽입형 심장 전자장치와 관련한 감염증의 발생 빈도는 높지 않으며, 반복되는 재
시술이 감염증 발생의 위험인자로 작용한다.  
---------------------------------------------------------------------------------------- 
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